Repligen (RGEN) to Release Earnings on Wednesday

Repligen (NASDAQ:RGEN) is set to post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Repligen to post earnings of $0.29 per share for the quarter. Repligen has set its FY 2024 guidance at 1.420-1.490 EPS and its FY24 guidance at $1.42-1.49 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. On average, analysts expect Repligen to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

Shares of RGEN opened at $171.28 on Wednesday. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 237.89, a P/E/G ratio of 5.16 and a beta of 1.02. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75. The business’s 50-day moving average is $186.62 and its 200-day moving average is $173.56.

Insider Buying and Selling at Repligen

In other Repligen news, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO James Bylund sold 4,373 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now directly owns 14,135 shares of the company’s stock, valued at $2,799,860.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 over the last 90 days. Insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RGEN. Stifel Nicolaus increased their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.